CV6 CEO Invited to Participate in Leading Biotech Europe CEO Event

CV6 CEO Invited to Participate in Leading Biotech Europe CEO Event

15th March 2019

Belfast, UK. 15th March, 2019.

CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that CEO and Founder Dr Robert Ladner has been invited to participate in the Europe CEO networking forum in Vienna, Austria on the 24th of March, 2019.

Europe CEO is an invitation-only networking meeting hosted by Leading Biotech that brings together CEOs and decision makers in the life sciences to participate in discussion panels, keynotes, and fireside chats featuring thought leaders and CEOs from several of the world’s leading biopharmaceutical companies as well as healthcare investors and leading researchers.

Dr Ladner will represent CV6 Therapeutics on a discussion panel entitled “Shifting the Paradigm; Encouraging a Culture of Entrepreneurship in Europe’s Biotech Industry”.  This discussion poses thought-provoking questions such as “What kind of people are needed to make a successful, sustainable biotech?” and “What changes are needed to encourage, recruit and retain a robust life science community throughout Europe?”.

Europe CEO is a satellite meeting held during Bio-Europe Spring®, an annual investor and networking conference that provides private and public biotechnology and life science companies with an opportunity to present and meet with investors and pharmaceutical executives. Bio-Europe Spring® takes place in Vienna, Austria from 25-27thof March, 2019.

CV6 Therapeutics

CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. To learn more about CV6 Therapeutics and its product pipeline including CV6-168, or to contact us, click here:  CV6 Therapeutics.